This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2003 Jan 11;361(9352):182-3; author reply 183-4.

doi: 10.1016/S0140-6736(03)12222-2.

Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility

Roland Fischer, Rainer Engelhardt

PMID: 12531618
DOI: 10.1016/S0140-6736(03)12222-2

Comment

Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility

Roland Fischer et al. Lancet. 2003.

. 2003 Jan 11;361(9352):182-3; author reply 183-4.

doi: 10.1016/S0140-6736(03)12222-2.

Authors

Roland Fischer, Rainer Engelhardt

PMID: 12531618
DOI: 10.1016/S0140-6736(03)12222-2

No abstract available

PubMed Disclaimer

Comment on

Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.
Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Anderson LJ, et al. Lancet. 2002 Aug 17;360(9332):516-20. doi: 10.1016/s0140-6736(02)09740-4. Lancet. 2002. PMID: 12241655

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science